Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

h and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form ... of special anti-vascular endothelial growth factor agents given by injection into the eye. ... have a scientific protocol for the many millions diagnosed with it. AMD usually ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug ... plant-derived compounds. BCC Research reveals in its new report that the U.S. ... defines the category and generates the most market demand. , BCC Research ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry ... their entire waste to energy process and continue to contribute to the sustainability ... , Temarry’s Waste to Energy process has been operating at their Mexico facility, ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... 13 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... Savient Pharmaceuticals,will present a corporate update at the upcoming ... is scheduled to begin on Tuesday, November 18, 2008 ... the St. Regis Hotel in New,York City November 18-19, ...
... Held Friday, November 14, 2008 at 9:00 a.m. Eastern ... ... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reports operational and,financial results ... year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged ...
... ILI ) today announced financial and business results ... Company reported a net loss of $1.6 million, or ... quarter of 2008 compared to a net,loss of $1.1 ... for the,same period last year., "Collaborations are an ...
Cached Biology Technology:Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Interleukin Genetics Reports Third Quarter 2008 Financial Results 2Interleukin Genetics Reports Third Quarter 2008 Financial Results 3Interleukin Genetics Reports Third Quarter 2008 Financial Results 4Interleukin Genetics Reports Third Quarter 2008 Financial Results 5Interleukin Genetics Reports Third Quarter 2008 Financial Results 6Interleukin Genetics Reports Third Quarter 2008 Financial Results 7
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... Ltd, a private company focused on the development of ... it has entered into a license agreement with the ... worldwide rights to develop and commercialise several novel kinase ... the CNIO,s considerable expertise in drug discovery and comprise ...
... have been officially declared extinct by the International Union for ... of Israel after some 60 years and turns out to ... living frogs. The Hula painted frog was catalogued ... discovered in the Hula Valley of Israel in the early ...
... the clear arguments for controlling parasitic infections, we know ... A good model system for research is provided by ... large intestines of pigs, slowing the animals, growth and ... are available to help keep the parasite in check ...
Cached Biology News:Stopping the worm from turning 2
... DNA Methylation Kit uses a simplified procedure ... methylation analysis. The kit is based on ... between cytosine and sodium bisulfite where cytosine ... Methylation Kits innovative in-column desulphonation reaction eliminates ...
... carbohydrate analysis standard is a lyophilized ... sugar alcohol; molecular weights range from ... provided for use with the Aminex ... kit for column testing or semiquantitative ...
... from KUBTEC is a dual capability system with ... representation of the specimen under test. While the ... images, the micro focus source also allows the ... standard 2D images. The 50 mm x 50 ...
... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
Biology Products: